Lavine J E
Division of Pediatric Gastroenterology and Nutrition, University of California, San Diego School of Medicine, and Children's Hospital and Health Center, 92103-8450, USA.
J Pediatr. 2000 Jun;136(6):734-8.
To determine whether supplemental oral vitamin E is effective in lowering serum aminotransferase and alkaline phosphatase levels in children with nonalcoholic steatohepatitis (NASH) associated with obesity.
Open-label pilot study enrolling all children <16 years old with chronically elevated serum aminotransferase (alanine aminotransferase and aspartate aminotransferase) levels for greater than 3 months, who demonstrated a diffusely echogenic liver on ultrasonography, had no demonstrable reason for abnormal serum chemistry values other than obesity, and therefore were diagnosed to have NASH. Patients were prescribed oral vitamin E between 400 and 1200 IU per day. Serum chemistry values were monitored monthly during treatment.
Eleven subjects with a mean age of 12.4 years were enrolled; treated patients were followed up for 4 to 10 months. The body mass index did not change significantly before and after treatment (32.8 +/- 3.8 kg/m(2) vs 32.5 +/- 4.4 kg/m(2), respectively). Serum alanine aminotransferase decreased from 175 +/- 106 IU/L to 40 +/- 26 IU/L (P <.001, paired Student t test), serum aspartate aminotransferase decreased from 104 +/- 61 IU/L to 33 +/- 11 IU/L (P <.002), and alkaline phosphatase decreased from 279 +/- 42 IU/L to 202 +/- 66 IU/L (P <.003) during treatment. Serum aminotransferase levels remained normal during treatment but returned to abnormal in those electing to stop treatment. Serum alpha-tocopherol levels were within the normal range before the commencement of therapy and increased significantly with supplementation. The liver remained diffusely echogenic during therapy, at the time serum aminotransferase levels were reduced.
Daily oral vitamin E administration normalized serum aminotransferase and alkaline phosphatase levels in children with NASH. Obese children with NASH should be encouraged to lose weight as part of a comprehensive weight reduction program and to consider taking supplemental alpha-tocopherol.
确定补充口服维生素E是否能有效降低肥胖相关非酒精性脂肪性肝炎(NASH)患儿的血清转氨酶和碱性磷酸酶水平。
开放标签的试点研究,纳入所有16岁以下血清转氨酶(丙氨酸转氨酶和天冬氨酸转氨酶)水平持续升高超过3个月的儿童,这些儿童在超声检查中显示肝脏弥漫性回声增强,除肥胖外无其他可证实的血清化学值异常原因,因此被诊断为患有NASH。患者每天服用400至1200国际单位的口服维生素E。治疗期间每月监测血清化学值。
招募了11名平均年龄为12.4岁的受试者;治疗患者随访4至10个月。治疗前后体重指数无显著变化(分别为32.8±3.8kg/m²和32.5±4.4kg/m²)。治疗期间,血清丙氨酸转氨酶从175±106IU/L降至40±26IU/L(P<.001,配对学生t检验),血清天冬氨酸转氨酶从104±61IU/L降至33±11IU/L(P<.002),碱性磷酸酶从279±42IU/L降至202±66IU/L(P<.003)。治疗期间血清转氨酶水平保持正常,但选择停止治疗的患者转氨酶水平恢复异常。治疗开始前血清α-生育酚水平在正常范围内,补充后显著升高。在血清转氨酶水平降低时,治疗期间肝脏仍保持弥漫性回声增强。
每日口服维生素E可使NASH患儿的血清转氨酶和碱性磷酸酶水平恢复正常。应鼓励患有NASH 的肥胖儿童作为综合减肥计划的一部分进行减肥,并考虑补充α-生育酚。